Chromatin tethering and retroviral integration: Recent discoveries and parallels with DNA viruses

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1799, Issue 3-4, 2010, Pages 182-191

  Meehan, Anne M ^a   Poeschla, Eric M ^a  

^a Mayo Clinic   (United States)

Author keywords

Chromatin; Herpesvirus; HIV 1; KSHV; LEDGF p75; Lentivirus; Tether

Indexed keywords

CELL PROTEIN; DIMER; INTEGRASE; LENS EPITHELIUM DERIVED GROWTH FACTOR; NUCLEAR PROTEIN; RETROVIRUS VECTOR;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN TETHERING; CONTROLLED STUDY; DNA VIRUS; ENZYME DEGRADATION; EPSTEIN BARR VIRUS; GENE THERAPY; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LENTIVIRINAE; NONHUMAN; PAPILLOMA VIRUS; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETROPOSON; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; SPUMA VIRUS; TARGET CELL; VIRUS ATTACHMENT; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS RESISTANCE; WART VIRUS;

ANIMALS; CHROMATIN; DNA VIRUSES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RETROVIRIDAE; VIRUS INTEGRATION;

DNA VIRUSES; HERPESVIRIDAE; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 77949268941     PISSN: 18749399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.10.001     Document Type: Review

References (145)

1. Varmus H.E., Shank P.R., Hughes S.E., Kung H.J., Heasley S., Majors J., Vogt P.K., and Bishop J.M. Synthesis, structure, and integration of the DNA of RNA tumor viruses. Cold Spring Harb. Symp. Quant. Biol. 43 (1979) 851-864
2. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. 276 (2001) 23213-23216
3. Poeschla E.M. Integrase, LEDGF/p75 and HIV replication. Cell. Mol. Life Sci. (2008) Feb 12; [Epub ahead of print]
4. Suzuki Y., and Craigie R. The road to chromatin-nuclear entry of retroviruses. Nat. Rev. Microbiol. 5 (2007) 187-196
5. Lin C.W., and Engelman A. The barrier-to-autointegration factor is a component of functional human immunodeficiency virus type 1 preintegration complexes. J. Virol. 77 (2003) 5030-5036
6. Farnet C.M., and Bushman F.D. HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 88 (1997) 483-492
7. Llano M., Vanegas M., Fregoso O., Saenz D.T., Chung S., Peretz M., and Poeschla E.M. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral pre-integration complexes. J. Virol. 78 (2004) 9524-9537
8. Soutoglou E., and Misteli T. Mobility and immobility of chromatin in transcription and genome stability. Curr. Opin. Genet. Dev. 17 (2007) 435-442
9. Misteli T. Beyond the sequence: cellular organization of genome function. Cell 128 (2007) 787-800
10. Cherepanov P., Maertens G., Proost P., Devreese B., Van Beeumen J., Engelborghs Y., De Clercq E., and Debyser Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278 (2003) 372-381
11. Esposito D., and Craigie R. HIV integrase structure and function. Adv. Virus Res. 52 (1999) 319-333
12. Dyda F., Hickman A.B., Jenkins T.M., Engelman A., Craigie R., and Davies D.R. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266 (1994) 1981-1986
13. Chen J.C., Krucinski J., Miercke L.J., Finer-Moore J.S., Tang A.H., Leavitt A.D., and Stroud R.M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8233-8238
14. Wang J.Y., Ling H., Yang W., and Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20 (2001) 7333-7343
15. Rice P.A., and Baker T.A. Comparative architecture of transposase and integrase complexes. Nat. Struct. Biol. 8 (2001) 302-307
16. Bushman F.D. Integration site selection by lentiviruses: biology and possible control. Curr. Top. Microbiol. Immunol. 261 (2002) 165-177
17. Muller H.P., and Varmus H.E. DNA bending creates favored sites for retroviral integration: an explanation for preferred insertion sites in nucleosomes. EMBO J. 13 (1994) 4704-4714
18. Wang G.P., Ciuffi A., Leipzig J., Berry C.C., and Bushman F.D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. (2007)
19. Hoffmann C., Minkah N., Leipzig J., Wang G., Arens M.Q., Tebas P., and Bushman F.D. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res. 35 (2007) e91
20. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., and Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 (2002) 521-529
21. Hematti P., Hong B.K., Ferguson C., Adler R., Hanawa H., Sellers S., Holt I.E., Eckfeldt C.E., Sharma Y., Schmidt M., von Kalle C., Persons D.A., Billings E.M., Verfaillie C.M., Nienhuis A.W., Wolfsberg T.G., Dunbar C.E., and Calmels B. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2 (2004) e423
22. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
23. Mitchell R.S., Beitzel B.F., Schroder A.R., Shinn P., Chen H., Berry C.C., Ecker J.R., and Bushman F.D. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2 (2004) E234
24. Nowrouzi A., Dittrich M., Klanke C., Heinkelein M., Rammling M., Dandekar T., von Kalle C., and Rethwilm A. Genome-wide mapping of foamy virus vector integrations into a human cell line. J. Gen. Virol. 87 (2006) 1339-1347
25. Trobridge G.D., Miller D.G., Jacobs M.A., Allen J.M., Kiem H.P., Kaul R., and Russell D.W. Foamy virus vector integration sites in normal human cells. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1498-1503
26. Lewinski M.K., Bisgrove D., Shinn P., Chen H., Hoffmann C., Hannenhalli S., Verdin E., Berry C.C., Ecker J.R., and Bushman F.D. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 79 (2005) 6610-6619
27. Lewinski M.K., Yamashita M., Emerman M., Ciuffi A., Marshall H., Crawford G., Collins F., Shinn P., Leipzig J., Hannenhalli S., Berry C.C., Ecker J.R., and Bushman F.D. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2 (2006) e60
28. Ge H., Si Y., and Roeder R.G. Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J. 17 (1998) 6723-6729
29. Nakamura H., Izumoto Y., Kambe H., Kuroda T., Mori T., Kawamura K., Yamamoto H., and Kishimoto T. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J. Biol. Chem. 269 (1994) 25143-25149
30. Nishizawa Y., Usukura J., Singh D.P., Chylack Jr. L.T., and Shinohara T. Spatial and temporal dynamics of two alternatively spliced regulatory factors, lens epithelium-derived growth factor (LEDGF/p75) and p52, in the nucleus. Cell. Tissue Res. 305 (2001) 107-114
31. Llano M., Vanegas M., Hutchins N., Thompson D., Delgado S., and Poeschla E.M. Identification and characterization of the chromatin binding domains of the HIV-1 integrase interactor LEDGF/p75. J. Mol. Biol. 360 (2006) 760-773
32. Turlure F., Maertens G., Rahman S., Cherepanov P., and Engelman A. A tripartite DNA-binding element, comprised of the nuclear localization signal and two AT-hook motifs, mediates the association of LEDGF/p75 with chromatin in vivo. Nucleic Acids Res. 34 (2006) 1663-1675
33. Vanegas M., Llano M., Delgado S., Thompson D., Peretz M., and Poeschla E. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLS-independent chromatin tethering. J. Cell. Sci. 118 (2005) 1733-1743
34. Maertens G., Cherepanov P., Debyser Z., Engelborghs Y., and Engelman A. Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase (IN) interactor LEDGF/p75. J. Biol. Chem. 279 (2004) 33421-33429
35. Maertens G., Cherepanov P., Pluymers W., Busschots K., De Clercq E., Debyser Z., and Engelborghs Y. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278 (2003) 33528-33539
36. Lever M.A., Th'ng J.P., Sun X., and Hendzel M.J. Rapid exchange of histone H1.1 on chromatin in living human cells. Nature 408 (2000) 873-876
37. Th'ng J.P., Sung R., Ye M., and Hendzel M.J. H1 family histones in the nucleus. Control of binding and localization by the C-terminal domain. J. Biol. Chem. 280 (2005) 27809-27814
38. Chen D., Dundr M., Wang C., Leung A., Lamond A., Misteli T., and Huang S. Condensed mitotic chromatin is accessible to transcription factors and chromatin structural proteins. J. Cell Biol. 168 (2005) 41-54
39. Phair R.D., Scaffidi P., Elbi C., Vecerova J., Dey A., Ozato K., Brown D.T., Hager G., Bustin M., and Misteli T. Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional genome scanning and dynamic interaction networks of chromatin proteins. Mol. Cell Biol. 24 (2004) 6393-6402
40. Cherepanov P., Devroe E., Silver P.A., and Engelman A. Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J. Biol. Chem. 279 (2004) 48883-48892
41. Bartholomeeusen K., Christ F., Hendrix J., Rain J.C., Emiliani S., Benarous R., Debyser Z., Gijsbers R., and De Rijck J. Lens epithelium-derived growth factor/p75 interacts with the transposase-derived DDE domain of PogZ. J. Biol. Chem. 284 (2009) 11467-11477
42. Maertens G.N., Cherepanov P., and Engelman A. Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin. J. Cell. Sci. 119 (2006) 2563-2571
43. Bartholomeeusen K., De Rijck J., Busschots K., Desender L., Gijsbers R., Emiliani S., Benarous R., Debyser Z., and Christ F. Differential interaction of HIV-1 Integrase and JPO2 with the C terminus of LEDGF/p75. J. Mol. Biol. 372 (2007) 407-421
44. Yokoyama A., and Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. [see comment]. Cancer Cell. 14 (2008) 36-46
45. Singh D.P., Ohguro N., Kikuchi T., Sueno T., Reddy V.N., Yuge K., Chylack Jr. L.T., and Shinohara T. Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. Biochem. Biophys. Res. Commun. 267 (2000) 373-381
46. Inomata Y., Hirata A., Koga T., Kimura A., Singh D.P., Shinohara T., and Tanihara H. Lens epithelium-derived growth factor: neuroprotection on rat retinal damage induced by N-methyl-d-aspartate. Brain Res. 991 (2003) 163-170
47. Sharma P., Singh D.P., Fatma N., Chylack Jr. L.T., and Shinohara T. Activation of LEDGF gene by thermal- and oxidative-stresses. Biochem. Biophys. Res. Commun. 276 (2000) 1320-1324
48. Matsui H., Lin L.R., Singh D.P., Shinohara T., and Reddy V.N. Lens epithelium-derived growth factor: increased survival and decreased DNA breakage of human RPE cells induced by oxidative stress. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2935-2941
49. Singh D.P., Ohguro N., Chylack Jr. L.T., and Shinohara T. Lens epithelium-derived growth factor: increased resistance to thermal and oxidative stresses. Invest. Ophthalmol. Vis. Sci. 40 (1999) 1444-1451
50. Nakamura M., Singh D.P., Kubo E., Chylack Jr. L.T., and Shinohara T. LEDGF: survival of embryonic chick retinal photoreceptor cells. Invest. Ophthalmol. Vis. Sci. 41 (2000) 1168-1175
51. Machida S., Chaudhry P., Shinohara T., Singh D.P., Reddy V.N., Chylack Jr. L.T., Sieving P.A., and Bush R.A. Lens epithelium-derived growth factor promotes photoreceptor survival in light-damaged and RCS rats. Invest. Ophthalmol. Vis. Sci. 42 (2001) 1087-1095
52. Sutherland H.G., Newton K., Brownstein D.G., Holmes M.C., Kress C., Semple C.A., and Bickmore W.A. Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol. Cell. Biol. 26 (2006) 7201-7210
53. M. Llano, J. Morrison, E.M. Poeschla, Virological and cellular roles of the transcriptional coactivator LEDGF/p75. Current Topics in Microbiology and Immunology (in press).
54. Caslini C., Yang Z., El-Osta M., Milne T.A., Slany R.K., and Hess J.L. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 67 (2007) 7275-7283
55. Hess J.L. Mechanisms of transformation by MLL. Crit. Rev. in Eukaryot. Gene Expr. 14 (2004) 235-254
56. Scacheri P.C., Davis S., Odom D.T., Crawford G.E., Perkins S., Halawi M.J., Agarwal S.K., Marx S.J., Spiegel A.M., Meltzer P.S., and Collins F.S. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genetics 2 (2006) e51
57. Yokoyama A., Somervaille T.C., Smith K.S., Rozenblatt-Rosen O., Meyerson M., and Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 (2005) 207-218
58. Roudaia L., and Speck N.A. A MENage a Trois in leukemia. [comment]. Cancer Cell. 14 (2008) 3-5
59. Llano M., Delgado S., Vanegas M., and Poeschla E.M. LEDGF/p75 prevents proteasomal degradation of HIV-1 integrase. J. Biol. Chem. 279 (2004) 55570-55577
60. Busschots K., Vercammen J., Emiliani S., Benarous R., Engelborghs Y., Christ F., and Debyser Z. The interaction of LEDGF/p75 with integrase is lentivirus-specific and promotes DNA binding. J. Biol. Chem. 280 (2005) 17841-17847
61. Cherepanov P. LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res. 35 (2007) 113-124
62. Engelman A., and Cherepanov P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathogens 4 (2008) e1000046
63. K. Busschots, A. Voet, M. De Maeyer, J.C. Rain, S. Emiliani, R. Benarous, L. Desender, Z. Debyser, F. Christ, Identification of the LEDGF/p75 binding site in HIV-1 integrase, J. Mol. Biol. 365 (2007) 1480-1492. S. Emiliani, A. Mousnier, K. Busschots, M. Maroun, B. Van Maele, D. Tempe, L. Vandekerckhove, F. Moisant, L. Ben-Slama, M. Witvrouw, F. Christ, J.C. Rain, C. Dargemont, Z. Debyser, R. Benarous, Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication, J Biol Chem 280 (2005) 25517-25523.
64. Bouyac-Bertoia M., Dvorin J., Fouchier R., Jenkins Y., Meyer B., Wu L., Emerman M., and Malim M.H. HIV-1 infection requires a functional integrase NLS. Molecular Cell. 7 (2001) 1025-1035
65. Dvorin J.D., Bell P., Maul G.G., Yamashita M., Emerman M., and Malim M.H. Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J. Virol. 76 (2002) 12087-12096
66. Limon A., Devroe E., Lu R., Ghory H.Z., Silver P.A., and Engelman A. Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import. J. Virol. 76 (2002) 10598-10607
67. Cherepanov P., Ambrosio A.L., Rahman S., Ellenberger T., and Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 17308-17313
68. Turlure F., Devroe E., Silver P.A., and Engelman A. Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci. 9 (2004) 3187-3208
69. Cherepanov P., Sun Z.Y., Rahman S., Maertens G., Wagner G., and Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat. Struct. Mol. Biol. 12 (2005) 526-532
70. Llano M., Saenz D.T., Meehan A., Wongthida P., Peretz M., Walker W.H., Teo W., and Poeschla E.M. An essential role for LEDGF/p75 in HIV integration. Science 314 (2006) 461-464
71. Hare S., Shun M.C., Gupta S.S., Valkov E., Engelman A., and Cherepanov P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathogens 5 (2009) e1000259
72. Shun M.C., Raghavendra N.K., Vandegraaff N., Daigle J.E., Hughes S., Kellam P., Cherepanov P., and Engelman A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 21 (2007) 1767-1778
73. Vandekerckhove L., Christ F., Van Maele B., De Rijck J., Gijsbers R., Van den Haute C., Witvrouw M., and Debyser Z. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J. Virol. 80 (2006) 1886-1896
74. Marshall H.M., Ronen K., Berry C., Llano M., Sutherland H., Saenz D., Bickmore W., Poeschla E., and Bushman F.D. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS ONE 2 (2007) e1340
75. Ciuffi A., Llano M., Poeschla E., Hoffmann C., Leipzig J., Shinn P., Ecker J.R., and Bushman F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11 (2005) 1287-1289
76. De Rijck J., Vandekerckhove L., Gijsbers R., Hombrouck A., Hendrix J., Vercammen J., Engelborghs Y., Christ F., and Debyser Z. Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J. Virol. 80 (2006) 11498-11509
77. Hombrouck A., De Rijck J., Hendrix J., Vandekerckhove L., Voet A., Maeyer M.D., Witvrouw M., Engelborghs Y., Christ F., Gijsbers R., and Debyser Z. Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog. 3 (2007) e47
78. Yu F., Jones G.S., Hung M., Wagner A.H., MacArthur H.L., Liu X., Leavitt S., McDermott M.J., and Tsiang M. HIV-1 integrase preassembled on donor DNA is refractory to activity stimulation by LEDGF/p75. Biochemistry 46 (2007) 2899-2908
79. Hayouka Z., Rosenbluh J., Levin A., Loya S., Lebendiker M., Veprintsev D., Kotler M., Hizi A., Loyter A., and Friedler A. Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8316-8321
80. McKee C.J., Kessl J.J., Shkriabai N., Dar M.J., Engelman A., and Kvaratskhelia M. Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J. Biol. Chem. 283 (2008) 31802-31812
81. Pandey K.K., Sinha S., and Grandgenett D.P. Transcriptional coactivator LEDGF/p75 modulates human immunodeficiency virus type 1 integrase-mediated concerted integration. J. Virol. 81 (2007) 3969-3979
82. Faure A., Calmels C., Desjobert C., Castroviejo M., Caumont-Sarcos A., Tarrago-Litvak L., Litvak S., and Parissi V. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res. 33 (2005) 977-986
83. Guiot E., Carayon K., Delelis O., Simon F., Tauc P., Zubin E., Gottikh M., Mouscadet J.F., Brochon J.C., and Deprez E. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J. Biol. Chem. 281 (2006) 22707-22719
84. Li M., Mizuuchi M., Burke Jr. T.R., and Craigie R. Retroviral DNA integration: reaction pathway and critical intermediates. EMBO J. 25 (2006) 1295-1304
85. Meehan A.M., Saenz D.T., Morrison J.H., Garcia-Rivera J.A., Peretz M., Llano M., and Poeschla E.M. LEDGF/p75 proteins with alternative chromatin tethers are functional HIV-1 cofactors. PLoS Pathogens 5 (2009) e1000522
86. Barbera A.J., Chodaparambil J.V., Kelley-Clarke B., Joukov V., Walter J.C., Luger K., and Kaye K.M. The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science 311 (2006) 856-861
87. Bednar J., Horowitz R.A., Grigoryev S.A., Carruthers L.M., Hansen J.C., Koster A.J., and Woodcock C.L. Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14173-14178
88. Harvey A.C., and Downs J.A. What functions do linker histones provide?. Mol. Microbiol. 53 (2004) 771-775
89. Hendzel M.J., Lever M.A., Crawford E., and Th'ng J.P. The C-terminal domain is the primary determinant of histone H1 binding to chromatin in vivo. J. Biol. Chem. 279 (2004) 20028-20034
90. Catez F., Ueda T., and Bustin M. Determinants of histone H1 mobility and chromatin binding in living cells. Nat. Struct. Mol. Biol. 13 (2006) 305-310
91. Barbera A.J., Chodaparambil J.V., Kelley-Clarke B., Luger K., and Kaye K.M. Kaposi's sarcoma-associated herpesvirus LANA hitches a ride on the chromosome. Cell Cycle 5 (2006) 1048-1052
92. Verma S.C., and Robertson E.S. Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol. Lett. 222 (2003) 155-163
93. Shinohara H., Fukushi M., Higuchi M., Oie M., Hoshi O., Ushiki T., Hayashi J., and Fujii M. Chromosome binding site of latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus is essential for persistent episome maintenance and is functionally replaced by histone H1. J. Virol. 76 (2002) 12917-12924
94. Roe T., Reynolds T.C., Yu G., and Brown P.O. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12 (1993) 2099-2108
95. Lewis P.F., and Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68 (1994) 510-516
96. Swanson J.A., and McNeil P.L. Nuclear reassembly excludes large macromolecules. Science 238 (1987) 548-550
97. Benavente R., Scheer U., and Chaly N. Nucleocytoplasmic sorting of macromolecules following mitosis: fate of nuclear constituents after inhibition of pore complex function. Eur. J. Cell Biol. 50 (1989) 209-219
98. Brown P.O. Integration. In: Coffin J.M., Hughes S.H., and Varmus H.E. (Eds). Retroviruses (1999), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 161-203
99. Ludtke J.J., Sebestyen M.G., and Wolff J.A. The effect of cell division on the cellular dynamics of microinjected DNA and dextran. [erratum appears in Mol Ther. 2002 Jul;6(1):134.]. Mol. Ther. 5 (2002) 579-588
100. Ciuffi A., Bushman F.D., and Retroviral D.N.A. integration: HIV and the role of LEDGF/p75. Trends Genet. 22 (2006) 388-395
101. Sears J., Ujihara M., Wong S., Ott C., Middeldorp J., and Aiyar A. The amino terminus of Epstein-Barr virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J. Virol. 78 (2004) 11487-11505
102. Wu H., Ceccarelli D.F., Frappier L., and The D.N.A. Segregation mechanism of Epstein-Barr virus nuclear antigen 1. EMBO Reports 1 (2000) 140-144
103. Hung S.C., Kang M.S., and Kieff E. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1865-1870
104. Sears J., Kolman J., Wahl G.M., and Aiyar A. Metaphase chromosome tethering is necessary for the DNA synthesis and maintenance of oriP plasmids but is insufficient for transcription activation by Epstein-Barr nuclear antigen 1. J. Virol. 77 (2003) 11767-11780
105. Ilves I., Kivi S., and Ustav M. Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which Is mediated by the viral E2 protein and its binding sites. J. Virol. 73 (1999) 4404-4412
106. You J., Croyle J.L., Nishimura A., Ozato K., and Howley P.M. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. [see comment]. Cell 117 (2004) 349-360
107. Oliveira J.G., Colf L.A., and McBride A.A. Variations in the association of papillomavirus E2 proteins with mitotic chromosomes. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1047-1052
108. Kirchner J., Connolly C.M., and Sandmeyer S.B. Requirement of RNA polymerase III transcription factors for in vitro position-specific integration of a retroviruslike element. Science 267 (1995) 1488-1491
109. Aye M., Irwin B., Beliakova-Bethell N., Chen E., Garrus J., and Sandmeyer S. Host factors that affect Ty3 retrotransposition in Saccharomyces cerevisiae. Genetics 168 (2004) 1159-1176
110. Chalker D.L., and Sandmeyer S.B. Ty3 integrates within the region of RNA polymerase III transcription initiation. Genes & Dev. 6 (1992) 117-128
111. Yieh L., Kassavetis G., Geiduschek E.P., and Sandmeyer S.B. The Brf and TATA-binding protein subunits of the RNA polymerase III transcription factor IIIB mediate position-specific integration of the gypsy-like element, Ty3. J. Biol. Chem. 275 (2000) 29800-29807
112. Zou S., Ke N., Kim J.M., and Voytas D.F. The Saccharomyces retrotransposon Ty5 integrates preferentially into regions of silent chromatin at the telomeres and mating loci. Genes Dev. 10 (1996) 634-645
113. Xie W., Gai X., Zhu Y., Zappulla D.C., Sternglanz R., and Voytas D.F. Targeting of the yeast Ty5 retrotransposon to silent chromatin is mediated by interactions between integrase and Sir4p. Mol. Cell. Biol. 21 (2001) 6606-6614
114. Zhu Y., Dai J., Fuerst P.G., and Voytas D.F. Controlling integration specificity of a yeast retrotransposon. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5891-5895
115. Dai J., Xie W., Brady T.L., Gao J., and Voytas D.F. Phosphorylation regulates integration of the yeast Ty5 retrotransposon into heterochromatin. Mol. Cell. 27 (2007) 289-299
116. Sandmeyer S. Integration by design. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5586-5588
117. Brady T.L., Fuerst P.G., Dick R.A., Schmidt C., and Voytas D.F. Retrotransposon target site selection by imitation of a cellular protein. Mol. Cell. Biol. 28 (2008) 1230-1239
118. Bowen N.J., Jordan I.K., Epstein J.A., Wood V., and Levin H.L. Retrotransposons and their recognition of pol II promoters: a comprehensive survey of the transposable elements from the complete genome sequence of Schizosaccharomyces pombe. Genome Res. 13 (2003) 1984-1997
119. Singleton T.L., and Levin H.L. A long terminal repeat retrotransposon of fission yeast has strong preferences for specific sites of insertion. Eukaryot. Cell 1 (2002) 44-55
120. Behrens R., Hayles J., and Nurse P. Fission yeast retrotransposon Tf1 integration is targeted to 5′ ends of open reading frames. Nucleic Acids Res. 28 (2000) 4709-4716
121. Chatterjee A.G., Leem Y.E., Kelly F.D., and Levin H.L. The chromodomain of Tf1 integrase promotes binding to cDNA and mediates target site selection. J. Virol. 83 (2009) 2675-2685
122. Leem Y.E., Ripmaster T.L., Kelly F.D., Ebina H., Heincelman M.E., Zhang K., Grewal S.I., Hoffman C.S., and Levin H.L. Retrotransposon Tf1 is targeted to Pol II promoters by transcription activators. Mol. Cell 30 (2008) 98-107
123. Tobaly-Tapiero J., Bittoun P., Lehmann-Che J., Delelis O., Giron M.L., de The H., and Saib A. Chromatin tethering of incoming foamy virus by the structural Gag protein. Traffic 9 (2008) 1717-1727
124. Moebes A., Enssle J., Bieniasz P.D., Heinkelein M., Lindemann D., Bock M., McClure M.O., and Rethwilm A. Human foamy virus reverse transcription that occurs late in the viral replication cycle. J. Virol. 71 (1997) 7305-7311
125. Ciuffi A., Diamond T.L., Hwang Y., Marshall H.M., and Bushman F.D. Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factor. Hum. Gene. Ther. 17 (2006) 960-967
126. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
127. Cavazzana-Calvo M., and Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet?. J. Clin. Invest. 117 (2007) 1456-1465
128. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., Gross F., Yvon E., Nusbaum P., Selz F., Hue C., Certain S., Casanova J.L., Bousso P., Deist F.L., and Fischer A. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
129. Gaspar H.B., Parsley K.L., Howe S., King D., Gilmour K.C., Sinclair J., Brouns G., Schmidt M., Von Kalle C., Barington T., Jakobsen M.A., Christensen H.O., Al Ghonaium A., White H.N., Smith J.L., Levinsky R.J., Ali R.R., Kinnon C., and Thrasher A.J. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
130. Fischer A., Hacein-Bey-Abina S., and Cavazzana-Calvo M. Gene therapy for immunodeficiency diseases. Semin. Hematol. 41 (2004) 272-278
131. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., Asnafi V., MacIntyre E., Dal Cortivo L., Radford I., Brousse N., Sigaux F., Moshous D., Hauer J., Borkhardt A., Belohradsky B.H., Wintergerst U., Velez M.C., Leiva L., Sorensen R., Wulffraat N., Blanche S., Bushman F.D., Fischer A., and Cavazzana-Calvo M. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118 (2008) 3132-3142
132. Howe S.J., Mansour M.R., Schwarzwaelder K., Bartholomae C., Hubank M., Kempski H., Brugman M.H., Pike-Overzet K., Chatters S.J., de Ridder D., Gilmour K.C., Adams S., Thornhill S.I., Parsley K.L., Staal F.J., Gale R.E., Linch D.C., Bayford J., Brown L., Quaye M., Kinnon C., Ancliff P., Webb D.K., Schmidt M., von Kalle C., Gaspar H.B., and Thrasher A.J. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118 (2008) 3143-3150
133. Pike-Overzet K., van der Burg M., Wagemaker G., van Dongen J.J., and Staal F.J. New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy. Mol. Ther. 15 (2007) 1910-1916
134. Cornetta K., Morgan R.A., and Anderson W.F. Safety issues related to retroviral-mediated gene transfer in humans. Hum. Gene. Ther. 2 (1991) 5-14
135. Donahue R.E., Kessler S.W., Bodine D., McDonagh K., Dunbar C., Goodman S., Agricola B., Byrne E., Raffeld M., Moen R., et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176 (1992) 1125-1135
136. Dave U.P., Jenkins N.A., and Copeland N.G. Gene therapy insertional mutagenesis insights. Science 303 (2004) 333
137. Li Z., Dullmann J., Schiedlmeier B., Schmidt M., von Kalle C., Meyer J., Forster M., Stocking C., Wahlers A., Frank O., Ostertag W., Kuhlcke K., Eckert H.G., Fehse B., and Baum C. Murine leukemia induced by retroviral gene marking. Science 296 (2002) 497
138. McCormack M.P., and Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. [see comment]. N Engl. J. Med. 350 (2004) 913-922
139. Modlich U., and Baum C. Preventing and exploiting the oncogenic potential of integrating gene vectors. [comment]. J. Clin. Invest. 119 (2009) 755-758
140. Montini E., Cesana D., Schmidt M., Sanvito F., Bartholomae C.C., Ranzani M., Benedicenti F., Sergi L.S., Ambrosi A., Ponzoni M., Doglioni C., Di Serio C., von Kalle C., and Naldini L. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. [see comment]. J. Clin. Invest. 119 (2009) 964-975
141. Hou Y., McGuinness D.E., Prongay A.J., Feld B., Ingravallo P., Ogert R.A., Lunn C.A., and Howe J.A. Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J. Biomol. Screen. 13 (2008) 406-414
142. Huang T.S., Myklebust L.M., Kjarland E., Gjertsen B.T., Pendino F., Bruserud O., Doskeland S.O., and Lillehaug J.R. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol. Cancer 6 (2007) 31
143. Kotin R.M., Linden R.M., and Berns K.I. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11 (1992) 5071-5078
144. Zhu Y., Zou S., Wright D.A., and Voytas D.F. Tagging chromatin with retrotransposons: target specificity of the Saccharomyces Ty5 retrotransposon changes with the chromosomal localization of Sir3p and Sir4p. Genes Dev. 13 (1999) 2738-2749
145. Moretti P., and Shore D. Multiple interactions in Sir protein recruitment by Rap1p at silencers and telemeres in yeast. Mol. Cell. Biol. 21 (2001) 8082-8094